Tarsus Pharmaceuticals Statistics
Total Valuation
TARS has a market cap or net worth of $1.21 billion. The enterprise value is $1.01 billion.
| Market Cap | 1.21B |
| Enterprise Value | 1.01B |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TARS has 37.50 million shares outstanding. The number of shares has increased by 19.35% in one year.
| Shares Outstanding | 37.50M |
| Shares Change (YoY) | +19.35% |
| Shares Change (QoQ) | +8.86% |
| Owned by Insiders (%) | 4.27% |
| Owned by Institutions (%) | 91.13% |
| Float | 24.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 69.40 |
| Forward PS | 12.11 |
| PB Ratio | 6.15 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 58.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.93, with a Debt / Equity ratio of 0.15.
| Current Ratio | 6.93 |
| Quick Ratio | 6.64 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.61 |
Financial Efficiency
Return on equity (ROE) is -74.30% and return on invested capital (ROIC) is -63.12%.
| Return on Equity (ROE) | -74.30% |
| Return on Assets (ROA) | -58.20% |
| Return on Capital (ROIC) | -63.12% |
| Revenue Per Employee | $71,504 |
| Profits Per Employee | -$556,939 |
| Employee Count | 244 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +120.86% in the last 52 weeks. The beta is 1.05, so TARS's price volatility has been similar to the market average.
| Beta (1Y) | 1.05 |
| 52-Week Price Change | +120.86% |
| 50-Day Moving Average | 33.76 |
| 200-Day Moving Average | 22.34 |
| Relative Strength Index (RSI) | 41.85 |
| Average Volume (30 Days) | 756,696 |
Short Selling Information
The latest short interest is 7.85 million, so 20.93% of the outstanding shares have been sold short.
| Short Interest | 7.85M |
| Short Previous Month | 7.20M |
| Short % of Shares Out | 20.93% |
| Short % of Float | 32.19% |
| Short Ratio (days to cover) | 10.57 |
Income Statement
In the last 12 months, TARS had revenue of $17.45 million and -$135.89 million in losses. Loss per share was -$4.62.
| Revenue | 17.45M |
| Gross Profit | 15.85M |
| Operating Income | -143.16M |
| Pretax Income | -135.89M |
| Net Income | -135.89M |
| EBITDA | -131.13M |
| EBIT | -132.55M |
| Loss Per Share | -$4.62 |
Balance Sheet
The company has $227.44 million in cash and $29.82 million in debt, giving a net cash position of $197.62 million or $5.27 per share.
| Cash & Cash Equivalents | 227.44M |
| Total Debt | 29.82M |
| Net Cash | 197.62M |
| Net Cash Per Share | $5.27 |
| Equity / Book Value | 196.99M |
| Book Value Per Share | 5.25 |
| Working Capital | 219.20M |
Cash Flow
In the last 12 months, operating cash flow was -$117.49 million and capital expenditures -$5.50 million, giving a free cash flow of -$123.00 million.
| Operating Cash Flow | -117.49M |
| Capital Expenditures | -5.50M |
| Free Cash Flow | -123.00M |
| FCF Per Share | -$4.19 |
Margins
Gross margin is 90.87%, with operating and profit margins of -820.53% and -778.89%.
| Gross Margin | 90.87% |
| Operating Margin | -820.53% |
| Pretax Margin | -778.89% |
| Profit Margin | -778.89% |
| EBITDA Margin | -751.58% |
| EBIT Margin | -759.71% |
| FCF Margin | -704.96% |
Dividends & Yields
TARS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.35% |
| Shareholder Yield | -19.35% |
| Earnings Yield | -11.22% |
| FCF Yield | -10.16% |
Analyst Forecast
The average price target for TARS is $48.17, which is 49.18% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $48.17 |
| Price Target Difference | 49.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 97.39% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TARS has an Altman Z-Score of 8.72 and a Piotroski F-Score of 1.
| Altman Z-Score | 8.72 |
| Piotroski F-Score | 1 |